Article Text
Abstract
Purpose To explore the prevalence and associated factors of parapapillary scleral ridges (PSRs).
Methods Out of the cohort of the population-based Beijing Eye Study (n=3468 participants), the study included all eyes with an axial length of ≥25 mm and a randomised sample of eyes with an axial length of <25 mm. Using optical coherence tomographic (OCT) images and fundus photographs, we examined the presence and height of PSRs, defined as a ridge-like structure located on the OCT scans in the parapapillary region.
Results The study cohort consisted of 366 eyes (314 individuals; mean age: 63.7±9.7 years). PSR prevalence increased from 0% in the non-myopic group to 3.8% (95% CI 0.3%, 7.3%) in moderately myopic group and 29.2% (95% CI 15.7%, 42.5%) in the highly myopic group. All PSRs were located in the temporal parapapillary gamma zone and corresponded to an ophthalmoscopically visible demarcation line running almost parallel to the optic disc border. Higher PRS prevalence correlated with longer axial length (OR 2.98; 95% CI 1.99, 4.46; p<0.001), female sex (OR 6.48; 95% CI 1.56, 27.0; p=0.01) and older age (OR 1.09; 95% CI 1.01, 1.18; p=0.02). Axial length had the strongest influence (beta: 0.48), followed by sex (beta: 0.20) and age (beta: 0.14). If age was dropped from the multivariable model, myopic maculopathy prevalence (OR 10.0; 95% CI 1.41,70.9; p=0.02) and stage (OR 3.57; 95% CI 1.21, 10.6; p=0.02) became significantly correlated with higher PSR prevalence.
Conclusions With a PSR prevalence of >60% in eyes with an axial length of >28 mm, PSRs are a common morphological feature of high myopia, with age and female sex as additional associated factors. PSRs may be due to a biomechanical interplay between the optic nerve and the posterior ocular segment of markedly axially elongated eyes.
- Retina
- Optic Nerve
Data availability statement
Data are available on reasonable request.
Statistics from Altmetric.com
Data availability statement
Data are available on reasonable request.
Footnotes
Contributors JBJ: Study design, data measurement, data analysis, manuscript writing, final improvement of manuscript, guarantor of overall work; SP-J: Study design, data measurement, data analysis, manuscript writing; JX: Data collection, data measurement; WW: Data collection, final improvement of manuscript; YXW: Study design, data measurement, manuscript writing, final improvement of manuscript, guarantor of overall work.
Funding National Natural Science Foundation of China (82271086).
Competing interests JBJ and SP-J: European patent EP 3 271 392, JP 2021-119187 and US 2021 0340237 A1: 'Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia. European patent application 23196899.1 'EGFR Antagonists for the treatment of diseases involving unwanted migration, proliferation and metaplasia of retinal pigment epithelium (RPE) cells'.
Provenance and peer review Not commissioned; externally peer reviewed.